Praxis precision medicines announces positive results of eeg analysis of prax-628 phase 1 study

Composite qeeg measure showed change from placebo after first dose of 5 mg effect in the composite qeeg measured through 10-day treatment period ongoing prax-628 phase 2 photo-paroxysmal response (ppr) expected to read out in 2h 2023 boston, aug. 07, 2023 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced the results from an analysis of eeg activity for subjects in the recent phase 1 study that demonstrated pharmacodynamic activity across all dose levels for study subjects who received prax-628 at first administration as compared with subjects who received placebo. prax-628 is a next generation functionally selective small molecule targeting the hyperexcitable state of sodium channels in the brain, which is currently being developed as a rapid acting, once daily, oral treatment for adult focal onset epilepsy.
PRAX Ratings Summary
PRAX Quant Ranking